Selection of Analytical Technology and Development of Analytical Procedures Using the Analytical Target Profile

被引:33
作者
Borman, Phil [4 ]
Campa, Cristiana [1 ]
Delpierre, Ghislain [2 ]
Hook, Elliot [3 ]
Jackson, Patrick [4 ]
Kelley, Wayne [5 ]
Protz, Michel [2 ]
Vandeputte, Olivier [2 ]
机构
[1] GSK, Vaccines, Tech Res & Dev, I-53100 Siena, Italy
[2] GSK, Analyt Res & Dev, B-1330 Rixensart, Belgium
[3] GSK, Pharma Supply Chain, Global Pharma Analyt Sci & Technol, Ware SG12 0DJ, Herts, England
[4] GSK, Med Res Ctr, Prod Dev & Supply, Stevenage SG1 2NY, Herts, England
[5] GSK, Prod Dev & Supply, King Of Prussia, PA 19406 USA
关键词
SIZE-EXCLUSION CHROMATOGRAPHY; PROTEIN; STRATEGIES; ANTIBODIES; THERAPIES; VECTORS; RNA;
D O I
10.1021/acs.analchem.1c03854
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A structured approach to method development can help to ensure an analytical procedure is robust across the lifecycle of its use. The analytical target profile (ATP), which describes the required quality of the reportable value to be produced by the analytical procedure, enables the analytical scientist to select the best analytical technology on which to develop their procedure(s). Once the technology has been identified, screening of potentially fit for purpose analytical procedures should take place. Analytical procedures that have been demonstrated to meet the ATP should be evaluated against business drivers (e.g., operational constraints) to determine the most suitable analytical procedure. Three case studies are covered from across small molecules, vaccines, and biotherapeutics. The case studies cover different aspects of the analytical procedure selection process, such as the use of platform method development processes and procedures, the development of multiattribute analytical procedures, and the use of analytical technologies to provide product characterization knowledge in order to define or redefine the ATP. Challenges associated with method selection are discussed such as where existing pharmacopoeial monographs link acceptance criteria to specific types of analytical technology.
引用
收藏
页码:559 / 570
页数:12
相关论文
共 51 条
[1]   Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route [J].
Afrough, Sara ;
Rhodes, Sophie ;
Evans, Thomas ;
White, Richard ;
Benest, John .
VACCINES, 2020, 8 (01)
[2]   Analysis of aggregates of human immunoglobulin G using size-exclusion chromatography, static and dynamic light scattering [J].
Ahrer, K ;
Buchacher, A ;
Iberer, G ;
Josic, D ;
Jungbauer, A .
JOURNAL OF CHROMATOGRAPHY A, 2003, 1009 (1-2) :89-96
[3]  
[Anonymous], 2020, AN PROC LIF PHARM FO, V46
[4]  
[Anonymous], 2009, Pharmaceutical Development
[5]  
[Anonymous], 1994, ICH Q2(R1) Validation of Analytical Procedures: Text andMethodology, Current Step 4 Version
[6]   Guidance to Achieve Accurate Aggregate Quantitation in Biopharmaceuticals by SV-AUC [J].
Arthur, Kelly K. ;
Kendrick, Brent S. ;
Gabrielson, John P. .
ANALYTICAL ULTRACENTRIFUGATION, 2015, 562 :477-500
[7]  
Barnett K. L., 2016, PHARMACOPEIAL FORUM, V42
[8]   Retargeting adenoviruses for therapeutic applications and vaccines [J].
Barry, Michael A. ;
Rubin, Jeffrey D. ;
Lu, Shao-Chia .
FEBS LETTERS, 2020, 594 (12) :1918-1946
[9]  
Borman P., 2010, SEPARATION SCI, V2, P2
[10]  
Borman P., 2010, PHARM TECHNOL EUR, V4, P38